Long-term outcomes of patients with Hepatitis C virus-related liver transplantation in a high-volume transplant center

Aim HCV is a major indication for liver transplantation (LT) in Europe, America, Australia and Japan. Virological recurrence after HCV-related LT is almost inevitable.We aimed to presantation long-term outcomes of patients LT due to hepatitis C. Materials and Methods We included 98 patients who had LT because of HCV-related liver disease at XXXXXXX University Faculty of Medicine between 2007 and 2022. The survival and recurrence rates of HCV patients and the factors that affected survival and recurrence were investigated. Treatment responses, long-term outcomes in patients had recurence were also analyzed. Results The average post-transplant survival time of 98 patients who had LT due to HCV was 11.91 ± 0.56 years, and 1, 3, 5,10-year survival rates were 95.7%, 88.3%, 82.2% ,75%.The HCV recurrence rate after transplantation was 50%. HCV-RNA positivity and HCV treatment before transplantation were statistically significant factors affecting recurrence. In recurrent patients, the highest rate of sustained virological response at 6 months (100%) was achieved with Maviret (100 mg glecaprevir − 40 mg pibrentasvir). We didn’t find any difference in survival rates between those with and without recurrence.Our findings suggest that survival rates after LT in HCV patients are satisfactory. Conclusion In addition, these results suggest that although the recurrence rate after transplantation is high, with effective treatments, patients with recurrence have a long survival time similar to patients without recurrence.